


## GSK8814

<b>Cat. No.:</b>	HY-114204
<b>CAS No.:</b>	1997369-78-4
<b>Molecular Formula:</b>	C <sub>28</sub> H <sub>35</sub> F <sub>2</sub> N <sub>5</sub> O <sub>3</sub>
<b>Molecular Weight:</b>	527.61
<b>Target:</b>	Epigenetic Reader Domain
<b>Pathway:</b>	Epigenetics
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	GSK8814 is a potent, selective, and ATAD2/2B bromodomain chemical probe and inhibitor, with a binding constant $pK_d=8.1$ and a $pK_i=8.9$ in BROMOscan. GSK8814 binds to ATAD2 and BRD4 BD1 with $pIC_{50}$ s of 7.3 and 4.6, respectively. GSK8814 shows 500-fold selectivity for ATAD2 over BRD4 BD1 <sup>[1]</sup> .		
<b>IC<sub>50</sub> &amp; Target</b>	ATAD2 8.9 (pKi)	ATAD2 8 nM (Ki)	BRD4 BD1 4.6 (pIC <sub>50</sub> )

### REFERENCES

- [1]. Bamborough P, et al. A Chemical Probe for the ATAD2 Bromodomain. *Angew Chem Int Ed Engl.* 2016 Sep 12;55(38):11382-6.
- [2]. Bamborough P, et al. Aiming to Miss a Moving Target: Bromo and Extra Terminal Domain (BET) Selectivity in Constrained ATAD2 Inhibitors. *J Med Chem.* 2018 Sep 27;61(18):8321-8336.

**Caution: Product has not been fully validated for medical applications. For research use only.**